Survival of transplant recipients after lymphoma diagnosis is influenced by KIR genotype. Survival is best in KIR2DL3 homozygous patients, who do not carry KIR2DL2 (2DL3/2DL3 53% ± 5%; 2DL2/2DL3 35% ± 8%; 2DL2/2DL2 32% ± 6%; A). KIR2DL2 and FCGR3A are independent and additive risk factors for death after lymphoma diagnosis. Stratifying patients by both KIR2DL2 and FCGR3A yields 4 prognostic groups, in which patients carrying KIR2DL2 and the FCGR3A alleles FF/VF show lowest survival (28% ± 5%), patients not carrying KIR2DL2 with FCGR3A VV genotype show best survival (71% ± 9%), and the remaining patients show intermediate survival (59% ± 12% for KIR2DL2⁺/FCGR3A VV patients and 49% ± 5% for KIR2DL2⁻/FCGR3A FF/VF patients, respectively; B).